Versartis, Inc. is a biotechnology company developing therapeutic proteins for the treatment of endocrine disorders. 

Versartis is developing new therapeutic proteins utilizing the novel half-life extension technology, XTEN. 

The company is interested in exploring partnerships on our products to accelerate the development process and ensure successful commercialization.

Apr 30 2013Journal of Clinical Endocrinology & Metabolism Publishes Positive Versartis Phase I Data

Jan 15 2013
Versartis Closes $25 Million Series C Financing Oct 24 2012
Versartis Initiates VERTICAL Trial of Long Acting Human Growth Hormone in Children with Growth Hormone Deficiency

Versartis Trial in Children to Assess Long-Acting Growth Hormone (VERTICAL)